Replagal

agalsidase alfa · Takeda Pharmaceuticals International AG Ireland Branch
AUTHORISED IN THE EU

What Replagal is used for

Replagal is indicated for long-term enzyme-replacement therapy in patients with a confirmed diagnosis of Fabry disease (?-galactosidase-A deficiency).

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Replagal
Active substance
agalsidase alfa
Disease area
Fabry Disease
Medicine group
Other alimentary tract and metabolism products
ATC code
A16AB03
Marketing authorisation holder
Takeda Pharmaceuticals International AG Ireland Branch
Authorised in the EU since
2001

Official information

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Replagal used for?

Replagal is indicated for long-term enzyme-replacement therapy in patients with a confirmed diagnosis of Fabry disease (?-galactosidase-A deficiency).

What is the active substance in Replagal?

Replagal contains agalsidase alfa.

Who makes Replagal?

The EU marketing authorisation holder is Takeda Pharmaceuticals International AG Ireland Branch.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.